TABLE 1
FROM:
Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation
S Ganepola, C Gentilini, U Hilbers, T Lange, K Rieger, J Hofmann, M Maier, U G Liebert, D Niederwieser, E Engelmann, R Heilbronn, E Thiel and L Uharek
BACK TO ARTICLETable 1. Characteristics of allografted patients
| n | |
|---|---|
| Sex | |
| Female | 17 |
| Male | 21 |
| Median age, range | |
| 49, 17–66 | |
| Underlying disease | |
| AML/MDS | 19 |
| ALL | 7 |
| CML | 8 |
| NHL | 4 |
| Donor | |
| Matched related | 8 |
| Matched unrelated | 30 |
| Stem cell source | |
| Peripheral blood stem cells | 38 |
| Conditioning regimen | |
| TBI/Flu | 8 |
| TBI/Cy | 16 |
| BU/Cy | 7 |
| Treo/Flu | 5 |
| Other | 2 |
| GVHD prophylaxis | |
| CSA/MTX | 27 |
| CSA/MMF | 6 |
| CSA | 4 |
| Other | 1 |
| Grade of GVHD | |
| I, II | 22 |
| III, IV | 4 |
| No GVHD | 12 |
| Donor/recipient CMV serostatus | |
| -/- (Group 1) | 5 |
| +/+ (Group 2) | 17 |
| +/- (Group 3) | 7 |
| -/+ (Group 4) | 9 |
| Risk group | |
| Intermediate (+/+, +/-) | 24 |
| High (-/+) | 9 |
| Low (-/-) | 5 |
Abbreviations: AML=acute myeloblastic leukaemia; BU=busulfan; CML=chronic myeloid leukemia; CMV=cytomegalovirus; CSA=cyclosporine A; Cy=cyclophosphamide; Flu=fludarabine; GVHD=graft-versus-host disease; MMF=mycofenolate mofetile; MTX=methotrexate; NHL=non-Hodgkin's lymphoma; TBI=total-body irradiation; Treol=treosulfan.
